
    
      This is a phase II, randomized, double-blind, placebo-controlled study of bermekimab in
      patients with moderate to severe atopic dermatitis. The primary objective of the study is to
      analyze the safety and efficacy of different dose regimens of bermekimab compared to placebo
      treatment in adult patients with moderate-to-severe AD. The study is multicenter and will
      consist of three groups:

      Treatment Arm 1: Bermekimab every week (qw)

      Treatment Arm 2: Bermekimab every other week (q2w)

      Arm 3 (Placebo): Placebo every week (qw)
    
  